9 Amendments of Marlene MORTLER related to 2021/2013(INI)
Amendment 278 #
Motion for a resolution
Paragraph 6 a (new)
Paragraph 6 a (new)
6 a. Considers it imperative to ensure broad and fact-based education and information about communicable and non-communicable diseases for adults as well as for children and adolescents, the treating and underlying causes thereof and healthy lifestyles in order to counteract misinformation and promote preventative actions; calls on the Commission to further support prevention measures and invest in research and promotion;
Amendment 329 #
Motion for a resolution
Paragraph 8
Paragraph 8
8. Welcomes the fact that the Commission will launch a pilot project to better understand the root causes of the delayed arrival of medicines on the market; further welcomes the fact that the Commission will continue to monitor mergers between pharmaceutical companies to avoid distortions of competition; stresses the need to reduce medicine approval times at national level and align them with European Medicines Agency (EMA) times, in order to ensure rapid and equal access to medicines, diagnostic services and prevention measures for everyone in the EU;
Amendment 437 #
Motion for a resolution
Paragraph 12 a (new)
Paragraph 12 a (new)
12 a. Stresses that Intellectual Property Rights incentivise research, development and innovation and ensure that European patients receive the latest and best scientific advances to address unmet medical needs; acknowledges, that market exclusivity for orphan drugs is a specific incentive for the development of new drugs for rare diseases;
Amendment 497 #
Motion for a resolution
Paragraph 13 a (new)
Paragraph 13 a (new)
13a. Emphasises that reliable and robust protection of intellectual property is vital for the development of new medicines and, in particular, for the promotion of research and development in Europe; takes the view that any restrictions on the protection of intellectual property will hamper the development of new medicines and undermine Europe's economic standing;
Amendment 615 #
Motion for a resolution
Paragraph 20
Paragraph 20
20. Supports the Commission in its efforts to conduct a structured dialogue with players in the pharmaceutical value chain, public authorities, non-governmental patient and health organisations and the research community to address weaknesses in the global medicines manufacturing and supply chain; emphasises that actions such as dual sourcing and safety stocks mitigate upcoming risks, increase resilience and the security of supply;
Amendment 632 #
Motion for a resolution
Paragraph 20 a (new)
Paragraph 20 a (new)
20 a. Recalls that localization policies may have adverse effects on the access to medicines; stresses that global networks and supply chains lower the dependency on one specific country or continent, which acts as an additional resilience factor;
Amendment 637 #
Motion for a resolution
Paragraph 20 b (new)
Paragraph 20 b (new)
20 b. Calls on the Commission to draft a harmonized definition of “shortages” and to standardize reporting requirements across Member States in order to enable closer cooperation and enhanced data exchange across Europe;
Amendment 638 #
Motion for a resolution
Paragraph 20 c (new)
Paragraph 20 c (new)
20 c. Calls on the Commission to audit the level of prevention, preparedness and response planning within the Member States; considers it imperative to consult with relevant stakeholders from the pharmaceutical and health sectors;
Amendment 639 #
Motion for a resolution
Paragraph 20 d (new)
Paragraph 20 d (new)
20 d. Considers it imperative to ensure a joint approach and procurement for safety stocks in each Member State; stresses that national stockpiles and capacities of critical medical products as well as of diagnostic services and tools and safety equipment contribute to the security of supply on Union level;